364 related articles for article (PubMed ID: 33599965)
21. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
[TBL] [Abstract][Full Text] [Related]
22. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
Karagodin I; Kalantari S; Yu DB; Kim G; Sayer G; Addetia K; Tayazime S; Weinert L; Yamat M; Uriel N; Lang R; Mor-Avi V
Int J Cardiovasc Imaging; 2020 Feb; 36(2):271-278. PubMed ID: 31583499
[TBL] [Abstract][Full Text] [Related]
23. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Vicent L; Esteban-Fernández A; Gómez-Bueno M; De-Juan J; Díez-Villanueva P; Iniesta ÁM; Ayesta A; González-Saldívar H; Rojas-González A; Bover-Freire R; Iglesias D; García-Aguado M; Perea-Egido JA; Martínez-Sellés M
J Cardiovasc Pharmacol; 2019 Feb; 73(2):118-124. PubMed ID: 30540687
[TBL] [Abstract][Full Text] [Related]
24. In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers: results from a retrospective cohort study.
De Vecchis R; Paccone A; Di Maio M
J Cardiovasc Med (Hagerstown); 2019 Dec; 20(12):857-858. PubMed ID: 31460889
[No Abstract] [Full Text] [Related]
25. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
[No Abstract] [Full Text] [Related]
26. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841
[No Abstract] [Full Text] [Related]
27. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
28. Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure.
Pinto G; Tondi L; Gemma M; De Marco A; Silipigni C; Spoladore R; Margonato A; Fragasso G
J Cardiovasc Pharmacol; 2019 May; 73(5):301-306. PubMed ID: 30855406
[TBL] [Abstract][Full Text] [Related]
29. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
30. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
[TBL] [Abstract][Full Text] [Related]
32. Sacubitril/valsartan (Entresto) for heart failure.
Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
[No Abstract] [Full Text] [Related]
33. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
34. Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome.
Cardelli LS; Magaldi M; Agullo A; Richard G; Nogue E; Berdague P; Galiner M; Georger F; Picard F; Prunet E; Molinari N; Bourdin A; Jaffuel D; Roubille F
Arch Cardiovasc Dis; 2024; 117(6-7):409-416. PubMed ID: 38811278
[TBL] [Abstract][Full Text] [Related]
35. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
Chen X; Schaufelberger M; Fu M
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
[TBL] [Abstract][Full Text] [Related]
36. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
[No Abstract] [Full Text] [Related]
37. New medications for heart failure.
Gordin JS; Fonarow GC
Trends Cardiovasc Med; 2016 Aug; 26(6):485-92. PubMed ID: 27038558
[TBL] [Abstract][Full Text] [Related]
38. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Sokos GG; Raina A
Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
[TBL] [Abstract][Full Text] [Related]
39. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.
Yandrapalli S; Khan MH; Rochlani Y; Aronow WS
Ther Adv Cardiovasc Dis; 2018 Aug; 12(8):217-231. PubMed ID: 29921166
[TBL] [Abstract][Full Text] [Related]
40. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
